Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for AVTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 -410.21M
March 31, 2026 -2.178M
December 31, 2025 -0.687M
September 30, 2025 -14.37M
June 30, 2025 -0.04M
March 31, 2025 0.00
December 31, 2024 -185.07M
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 -0.001M
September 30, 2023 -25.94M
June 30, 2023 -6.598M
March 31, 2023 -13.75M
December 31, 2022 -0.082M
September 30, 2022 0.00
June 30, 2022 -0.025M
March 31, 2022 0.00
December 31, 2021 -0.076M
September 30, 2021 -34.36M
June 30, 2021 -1.603M
March 31, 2021 -37.82M
December 31, 2020 -0.201M
September 30, 2020 0.00
Date Value
June 30, 2020 -35.58M
March 31, 2020 -9.098M
September 30, 2019 -3.739M
June 30, 2019 -0.2902M
March 31, 2019 -9.070M
December 31, 2018 -6.324M
September 30, 2018 -3.975M
June 30, 2018 -0.0355M
March 31, 2018 -0.3634M
December 31, 2017 0.2678M
September 30, 2017 -0.2792M
June 30, 2017 -4.913M
March 31, 2017 -1.187M
December 31, 2016 -0.8882M
September 30, 2016 -1.00M
June 30, 2016 -0.041M
March 31, 2016 0.041M
December 31, 2015 -21.41M
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -10.49M
Incyte Corp. -75.15M
AbbVie, Inc. 9.00M
Rezolute, Inc. -0.747M
Alnylam Pharmaceuticals, Inc. -33.56M